Unraveling Batten Disease

English
Waste management is a big issue anywhere, but at the cellular level it can be a matter of life and death. A Weizmann Institute study, published in the Journal of Cell Biology, has revealed what causes a molecular waste container in the cell to overflow in Batten disease, a rare but fatal neurodegenerative disorder that begins in childhood. The findings may form the basis for a therapy for this disorder.
 
In Batten disease, an insoluble yellow pigment accumulates in the brain’s neurons, causing these cells to degenerate and ultimately die. Patients gradually become disabled, losing their vision and motor skills and suffering mental impairment; they rarely survive beyond their early twenties. It’s been known for a while that the disorder is caused by a mutation in the gene referred to as CLN3, but the role of this gene in the cell was unknown. This role has now been discovered in the Weizmann Institute study, explaining the molecular dysfunction in Batten disease.

 
The research was conducted in the laboratory of Prof. Jeffrey Gerst of the Molecular Genetics Department by Rachel Kama and postdoctoral fellow Dr. Vydehi Kanneganti, in collaboration with Prof. Christian Ungermann of the University of Osnabrueck in Germany. All the studies were performed in yeast: The yeast equivalent of the mammalian CLN3 gene has been conserved almost intact in the course of the evolution, making them ideal models for study. In fact, so similar are the yeast and the mammalian genes that when the researchers replaced a missing copy of the yeast gene with a working copy of mammalian CLN3, normal functioning of the yeast cell was restored.
 
The experiments showed that the yeast equivalent of CLN3 is involved in moving proteins about the cell – the scientific term is “protein trafficking.” The gene activates an enzyme of the kinase family, which, in turn, launches a series of molecular events regulating the trafficking. When the yeast CLN3 is mutated, this trafficking is disrupted. As a result, certain proteins accumulate abnormally in the lysosome, the cell’s waste-recycling machine, instead of being transported to another destination. At some point the lysosome is filled beyond capacity; it then interferes with molecular signaling and other vital processes in the neuron, eventually killing the cell.
 
A great deal of research must still be performed before this finding benefits humans, but the clarification of the CLN3 function is precisely what might help develop a new therapy. Replacing the defective CLN3 in all the brain’s neurons is a daunting challenge, but replacing its function – for example, by activating the relevant kinase by means of a drug – should be much more feasible.  
 
Prof. Jeffrey Gerst’s research is supported by the Miles and Kelly Nadal and Family Laboratory for Research in Molecular Genetics; the Hugo and Valerie Ramniceanu Foundation; the Y. Leon Benoziyo Institute for Molecular Medicine; the Yeda-Sela Center for Basic Research; the estate of Raymond Lapon; the National Contest for Life (NCL) Stiftung, Germany; and the Israel Science Foundation, Israel. Prof. Gerst is the incumbent of the Besen-Brender Professorial Chair of Microbiology and Parasitology.


 
Life Sciences
English

New Job for a Busy Protein

English

 

(l-r) Prof. Varda Rotter, Dr. Eldad Tzahor, Dr. Ariel Rinon, Alina Molchadsky and Dr. Rachel Sarig. Migration regulation

 

“If you want something done, ask a busy person to do it.” On second thought this advice (originally from Lucille Ball), makes quite a bit of sense. So it is no wonder that the protein p53, which works in our cells day and night to keep cancer at bay, has also been handed an important task in embryonic development. This finding emerged from research conducted by Dr. Eldad Tzahor of the Biological Regulation Department, whose expertise includes embryonic development, and Prof. Varda Rotter of the Molecular Cell Biology Department, a pioneer of p53 research.


Sometimes called the “guardian of the genome,” p53 puts the brakes on processes that could lead to cancer when the cell’s genetic material is injured. But scientists who in the past looked for a role for p53 in embryonic development had concluded that its “day job” was keeping it busy enough: “Erasing” the gene in mouse embryos did not affect their development (though, unsurprisingly, they did develop cancer early on). Nonetheless, recent findings hinted at p53 involvement in the process of embryonic cell differentiation, suggesting that the previous conclusion needed reexamining.


“It is illogical to think that a crucial protein like p53 would play no role at all in embryonic development,” says Tzahor. “What actually happens in the mice missing the gene is that the genetic system is completely “rewired” to compensate for the protein’s loss. Other proteins cover for it, and while this enables development to proceed, it also frustrates the efforts of scientists to get at the mechanisms underlying that development.” To overcome this difficulty, the scientists targeted the p53 protein or its activity at only a limited number of sites, and only at certain times, so that the cell didn’t have a chance to cover for the lost protein.


The researchers focused on a group of cells called neural crest cells, which are tied to the development of the face, brain and peripheral nervous system. These early cells differentiate into a number of types, including nerve cells, facial cartilage, pigment-producing cells and more. Before their rapid differentiation, these cells undergo another process, called epithelial mesenchymal transition (EMT), which enables them to begin migrating from their original site in the neural tube – the embryonic template of the central nervous system – to the facial area.


This key process is similar in many respects to processes that cancer cells undergo when they become malignant. And this suggested to the researchers that p53, which is found to malfunction in a high percentage of cancers, might play a role in regulating EMT. To investigate, Tzahor’s group, which included research students Ariel Rinon and Elisha Nathan, and Dr. Rachel Sarig, first asked whether p53 does, after all, play any sort of role in embryonic development. They found that mouse embryos lacking p53 did indeed have mild defects in their facial structure. Next, the team used chicken embryos to pinpoint both the timing and location of p53 activation. Although the protein was present in the neural crest cells, they discovered that it was silenced for the duration of the EMT process.


The researchers concluded that the reduction in p53 was a necessary condition for EMT. To investigate further, they artificially stabilized levels of the protein; and this was the result: EMT was indeed reduced with fewer neural crest cells migrating out of the neural tube, there was a drop in the expression of EMT-related genes and there were structural defects in the face and brain. Conversely, when the researchers delayed p53 activity, they found an excess of neural crest cells along with increased proliferation. Additional experiments with mouse embryonic cells by research student Alina Molchadsky in Rotter’s lab confirmed these findings: Without p53, there is an increase in the expression of genes tied to EMT as well as those involved in cell division. These findings recently appeared in the journal Development.

 

Neural crest cell migration in a chicken embryo

 

 

Tzahor: “p53 puts the brakes on cell division, and this is what prevents cancer. Its levels need to drop for neural crest cells to divide and migrate, but a drop beyond that which takes place naturally during EMT is harmful as well.”


The study’s findings hint that p53 links two parallel developmental processes – cell division/proliferation and EMT. But they may also have relevance for cancer studies: “We have known for a long time that cancer processes are similar to those of embryonic development, only deregulated and uncontrolled,” says Tzahor. “But much less is known about the connections between p53, cell migration and tumor growth. Our study has not only identified yet another job assigned to p53, it also points to promising new directions in cancer research.”
 

Prof. Varda Rotter's research is supported by the Yad Abraham Research Center for Cancer Diagnostics and Therapy, which she heads; the Women's Health Research Center, which she heads; the Jeanne and Joseph Nissim Family Foundation for Life Sciences; the Leir Charitable Foundations; the Centre Leon Berard Lyon; Donald Schwarz, Sherman Oaks, CA; and the estate of John M. Lang. Prof. Rotter is the incumbent of the Norman and Helen Asher Professorial Chair of Cancer Research.


Dr. Eldad Tzahor's research is supported by the Kahn Family Research Center for Systems Biology of the Human Cell; the Helen and Martin Kimmel Institute for Stem Cell Research; the Kirk Center for Childhood Cancer and Immunological Disorders; the Jeanne and Joseph Nissim Foundation for Life Sciences Research; the Yeda-Sela Center for Basic Research; the estate of Jack Gitlitz; the Women's Health Research Center funded by the Bennett-Pritzker Endowment Fund, the Marvelle Koffler Program for Breast Cancer Research, the Harry and Jeanette Weinberg Women's Health Research Endowment and the Oprah Winfrey Biomedical Research Fund; and the estate of Fannie Sherr. Dr. Tzahor is the incumbent of the Gertrude and Philip Nollman Career Development Chair.

 

(l-r) Prof. Varda Rotter, Dr. Eldad Tzahor, Dr. Ariel Rinon, Alina Molchadsky and Dr. Rachel Sarig. Migration regulation
Life Sciences
English

Antioxidants: Food Supplement or Birth Control?

English

(l-r) Ari Tadmor, Prof. Nava Dekel and Dr. Ketty Shkolnik. Active ingredient

 

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antioxidants are sold over the counter everywhere. They’re added to food, drink and even face cream. But according to Prof. Nava Dekel of the Biological Regulation Department, we still don’t have a complete understanding of how they act in our bodies. New research by Dekel and her team, recently published in the Proceedings of the National Academy of Sciences, USA, (PNAS), has revealed a possible unexpected side effect of antioxidants: They might cause fertility problems in females.
 
 
Common antioxidants include vitamins C and E. These work by eliminating molecules called reactive oxygen species that are produced naturally in the body. Stress can cause these chemically active molecules to be overproduced, and in large amounts they damage cells indiscriminately. By neutralizing these potentially harmful substances, antioxidants may, theoretically, improve health and slow down the aging process.
 
 
But when Dekel and her research team, including her former and present Ph.D. students Dr. Ketty Shkolnik and Ari Tadmor, applied antioxidants to the ovaries of female mice, the results were surprising: ovulation levels dropped precipitously. That is, very few eggs were released from the ovarian follicles to reach the site of fertilization, compared to those in untreated ovaries.
 
 
Pregnant Venus. The other side of stress molecules
 

To understand what lies behind these initial findings, the team asked whether it is possible that the process of ovulation might rely on the very “harmful” substances destroyed by antioxidants – reactive oxygen species.

 
 Further testing in mice showed that this is, indeed, the case. In one experiment, for instance, Dekel and her team treated some ovarian follicles with luteinizing hormone, the physiological trigger for ovulation, and others with hydrogen peroxide, a reactive oxygen species. The results showed hydrogen peroxide fully mimicked the effect of the ovulation-inducing hormone. This implies that reactive oxygen species that are produced in response to luteinizing hormone serve, in turn, as mediators for this physiological stimulus leading to ovulation.
 
Among other things, these results help fill in a picture of fertility and conception that has begun to emerge in recent years, in which it appears that these processes share a number of common mechanisms with inflammation. It makes sense, says Dekel, that substances which prevent inflammation in other parts of the body might also get in the way of normal ovulation, and so more caution should be exercised when administering such substances.
 
Much of Dekel’s research has focused on fertility – her previous results are already helping some women become pregnant. Ironically, the new study has implications for those seeking the opposite effect. Dekel: “On the one hand, these findings could prove useful to women who are having trouble getting pregnant. On the other, further studies might show that certain antioxidants might be an effective means of birth control that could be safer than today’s hormone-based prevention.”
 
Dekel and her team are now planning further studies to investigate the exact mechanics of this step in ovulation and to examine antioxidant effects on mice when administered in either food or drink. In addition, they plan to collect data on the possible link between females, antioxidant supplements and difficulty in conceiving.
 
Prof. Nava Dekel's research is supported by the M.D. Moross Institute for Cancer Research; the Y. Leon Benoziyo Institute for Molecular Medicine; the Jeanne and Joseph Nissim Foundation for Life Sciences Research; the Yeda-Sela Center for Basic Research; the Willner Family Center for Vascular Biology Head; the Dwek Family Biomedical Research Fund; the Phyllis and Joseph Gurwin Fund for Scientific Advancement; the J&R Foundation; la Fondation Raphael et Regina Levy; and Allyson Kaye, UK. Prof. Dekel is the incumbent of the Philip M. Klutznick Professorial
Chair of Developmental Biology.
 
 
Pregnant Venus. The other side of stress molecules
Life Sciences
English

GOT to Prevent Brain Damage

English
Prof. Vivian Teichberg. New support for the approach

 

Two studies recently conducted in Spain provide conclusive evidence for the effectiveness of a novel approach, developed at the Weizmann Institute, to treating stroke, head trauma and other diseases of the brain.
 
In 2003, Prof. Vivian I. Teichberg of the Neurobiology Department demonstrated a way to remove excess glutamate – a short-lived neurotransmitter – from the brain. Glutamate gets overproduced by injured brain cells, and the overdose kills off yet more cells. Teichberg knew that the body maintains a balance between glutamate levels in the blood and in the brain, and he hypothesized that removing glutamate from the blood would force tiny pumps (called transporters) on the brain’s blood vessels to shunt glutamate out of the brain and into the blood. By 2007, he and his colleagues had shown that rats given GOT – an enzyme that “scavenges” glutamate from blood – were protected against the worst damage from head trauma.
 
In the first of the new studies, Fransisco Campos and others in the lab of Prof. Jose Castillo, the University of Santiago de Compostela, Spain, worked with animal models of stroke. Injecting rats with a blood glutamate scavenger reduced glutamate levels in the brain, and also lessened cell death and swelling. In the second study, hospital neurologists in Spain tested newly admitted stroke patients for blood glutamate and GOT, and they found these two substances to be the best predictors of recovery at three months. High glutamate levels correlated with a poorer prognosis, high GOT levels with a better one.
 
A number of diseases, including Alzheimer’s, Parkinson’s and even some brain tumors involve elevated glutamate levels in the brain, and human GOT might, in the future, be used to treat a wide range of problems. Yeda, the technology transfer arm of the Weizmann Institute, holds a patent for this method.
 
Prof. Vivian I. Teichberg's research is supported by the Nella and Leon Benoziyo Center for Neurosciences; the Carl and Micaela Einhorn-Dominic Brain Research Institute; and the Legacy Heritage Fund Program of the Israel Science Foundation. Prof. Teichberg is the incumbent of the Louis and Florence Katz-Cohen Professorial Chair of Neuropharmacology.
 

 
 
Prof. Vivian Teichberg. New support for the approach
Life Sciences
English

Fat Chance for Health

English

Dr. Karina Yaniv. New growth

 


We all care about having healthy levels of cholesterol and other fats in our blood, but our blood vessels themselves don’t seem to care. Even when plaques of fat threaten to block the flow of blood, the vessels fail to respond to the danger, when they might, for instance, sprout new branches. Conventional wisdom has it that the vessels don’t “know” the fat is there. But don’t they? And wouldn’t it be wonderful if they did sense the danger and branched out to bypass the blockage, thus preventing heart attacks?

Exploring the relationship between blood vessels and fat is one of the two major projects in the lab of Dr. Karina Yaniv, who recently joined the Biological Regulation Department as a senior scientist. She addresses this question as part of a more general theme: clarifying how blood vessels form in the embryo.
 
The cells that form blood vessels, called endothelial cells, have long been known to be sensitive to blood oxygen levels: If these levels drop, new vessels grow in the vicinity to ensure the surrounding tissue gets an adequate oxygen supply. As for fat, until now scientists believed that the vessels didn’t “feel” its presence. Yet during her postdoctoral studies at the National Institutes of Health in the United States, Yaniv provided the first experimental evidence for a new hypothesis according to which endothelial cells are attuned to the fat availability in their environment and respond accordingly. Using zebrafish as a model, her research revealed that when fat supply is low, developing zebrafish embryos grow extra blood vessels, probably to ensure adequate levels of vital nutrients. After all, the embryo is nourished mainly by fat molecules, such as those in egg yolk. When fat is plentiful, vessel growth in the embryo comes to a halt.

In adulthood, this biochemical dialogue between fat and blood vessel walls could be misfiring: High cholesterol levels in the blood might be preventing collateral vessels from growing, even though such growth is precisely what’s needed to prevent blood vessel blockage. In her new lab at the Weizmann Institute, Yaniv seeks to identify the molecular signals exchanged between fats and the endothelial cells of the blood vessel walls.
 
Understanding how blood vessel growth is regulated could have important implications for human health, possibly even enabling the regulation of such growth on demand. Helping the body grow new vasculature could be beneficial after a heart attack or stroke, or in preventing these events. Conversely, in cancer, selectively blocking the formation of new blood vessels that feed the tumor could help in treating malignancy.
 
 

Zebrafish Vessel Formation in vivo

 


This movie shows timelapse multiphoton confocal images of vessel dynamics in fli-EGFP transgenic zebrafish. Elongating angiogenic sprouts migrate between the somites to give rise to a dorsal branch. Highly dynamic behavior involving extension and retraction of numerous filopodia can be seen as the sprouts extend dorsally.

 
 
 

Zebrafish do have a lymphatic system


When not studying the development of blood vessels in the embryo,  Yaniv focuses on the lymphatic system, which is essential for the immune response, fluid metabolism and fat absorption. During her postdoctoral research, she showed that, contrary to common belief, zebrafish do have a lymphatic system. Thanks to her research, several labs in the United States and Europe have started using zebrafish in their studies of the lymphatic system. Yaniv also provided the first in vivo evidence in support of a century-old hypothesis concerning the origin of the lymphatic system: Her studies showed that in the vertebrate embryo, the lymph vessels originate in the veins. Because the lymphatic system is involved in numerous disease processes, this research, too, could help in the treatment of disease. In particular, metastatic cells use the lymphatic network to migrate to distant organs; knowing in greater detail how lymph vessels form during embryonic development might make it possible to block their growth around a malignant tumor, preventing the spread of metastasis.

Yaniv has chosen to conduct her studies on zebrafish because they offer an excellent model for her genetic research. Their small size allows her to keep a staggering 12,000 fish in 400 one-foot-high aquaria in an average-size lab. In the transparent embryos, blood and lymph vessels are easily visualized. Moreover, their genes are convenient to manipulate: Though all the fish swimming merrily in Yaniv’s aquaria look identical, sporting the same “zebra” stripes, some are transgenic, their genomes containing “reporter” genes that emit a glow marking particular DNA segments, while others are mutant, missing certain genes. The range of mutants prepared by Yaniv’s lab promises to help reveal numerous genetic secrets vital for human health.
 
 
 

Development of the Lymphatic Vascular System in Zebrafish

 

This movie shows two-photon time-lapse images of transgenic zebrafish expressing GFP in the nuclei of endothelial cells. Two lymphatic endothelial progenitors and their daughters have been highlighted in yellow and red for ease of tracking. Endothelial nuclei in the midline of the embryo migrate rostrally and then ventrally. Just ventral to the dorsal aorta they divide and the daughter cells incorporate into the wall of the newly formed thoracic duct - the main lymphatic vessel of the fish.
 
 


Creative time management

 
Born in Cordoba, Argentina, Dr. Karina Yaniv immigrated to Israel in 1989 as part of a Zionist youth movement program. After a year on Kibbutz Magal, she enrolled in the Hebrew University of Jerusalem, earning a Ph.D. in developmental biology from Hadassah Medical School in 2005. She then conducted postdoctoral research at the National Institutes of Health in Bethesda, Maryland, and joined the Weizmann Institute faculty in the summer of 2009. Yaniv is married to Ram, a software engineer, and is a mother of three: Yotam, 12, Nitay, 9 and Eylon, 4. She says combining motherhood with scientific research takes creative time management, such as taking a break from work in the afternoon and resuming it late at night. Working hard is part of her nature: “If you do something you love, you want to do it well,” she says.
 

Dr. Karina Yaniv's research is supported by the Willner Family Center for Vascular Biology; the Carolito Stiftung; the Abraham and Sonia Rochlin Foundation; Lois Rosen, Los Angeles, CA; the estate of David Arthur Barton; the estate of Paul Ourieff; and the estate of George Talis.

 
Dr. Karina Yaniv. New growth
Life Sciences
English

Hope for Stroke Victims

English

Two new studies support a novel approach based on Weizmann Institute scientists’ research

 
Much of the devastation of stroke and head trauma is due to damage caused by the overproduction of a substance in the brain called glutamate. Preventing this damage has been impossible, until now, as many drugs don’t cross the so-called blood-brain barrier, and those that do often don’t work as intended. But a method originally devised at the Weizmann Institute of Science may, in the future, offer a way to avert such glutamate-induced harm.
 
Prof. Vivian I. Teichberg of the Institute’s Neurobiology Department first demonstrated a possible way around these problems in 2003. Glutamate – a short-lived neurotransmitter – is normally all but absent in brain fluids. After a stroke or injury, however, the glutamate levels in brain fluid become a flood that over-excites the cells in its path and kills them. Instead of attempting to get drugs into the brain, Teichberg had the idea that one might be able to transport glutamate from the brain to the blood using the tiny “pumps,” or transporters, on the capillaries that work on differences in glutamate concentration between the two sides. Decreasing glutamate levels in blood would create a stronger impetus to pump the substance out of the brain. He thought that a naturally-occurring enzyme called glutamate-oxaloacetate transaminase (GOT, for short) could “scavenge” blood glutamate, significantly lowering its levels. By 2007, Teichberg and his colleagues had provided clear evidence of the very strong brain neuroprotection that oxolacetate (a chemical similar to GOT) afforded rats exposed to a head trauma.
 
Two new studies – conducted by Fransisco Campos and others from the lab of Prof. Jose Castillo in the University of Santiago de Compostela, Spain – now provide a definitive demonstration of Teichberg’s results. In the first, the scientists conclusively showed that oxoloacetate injected into rats with stroke-like brain injuries reduces glutamate levels both in the blood and in the affected brain region, while significantly lessening both cell death and the swelling that can accompany stroke. In the second, a team of neurologists in two different hospitals checked the levels of glutamate and GOT in several hundred stroke victims who were admitted to their hospitals. They found that the most significant predictor of the prognosis – how well they would recover at three months and how much brain damage they would suffer – was the levels of these two substances. High glutamate levels correlated with a poor outcome, high GOT levels with a better one.
 
The overall implication of these two papers is that administering GOT might improve a patient’s chances of recovering, as well as speeding up the process. In addition to stroke and head trauma, a number of diseases are characterized by an accumulation of glutamate in the brain, including Alzheimer’s disease, Parkinson, multiple sclerosis, epilepsy, glaucoma, certain brain tumors and amyotrophic lateral sclerosis, and there is hope that, in the future, treatments to scavenge glutamate could relieve the symptoms and improve the outcomes for a number of neurological problems. Yeda, the technology transfer arm of the Weizmann Institute, holds a patent for this method.
 
 
Prof. Vivian I. Teichberg’s research is supported by the Nella and Leon Benoziyo Center for Neurosciences; the Carl and Micaela Einhorn-Dominic Brain Research Institute; and the Legacy Heritage Fund Program of the Israel Science Foundation. Prof. Teichberg is the incumbent of the Louis and Florence Katz-Cohen Professorial Chair of Neuropharmacology.
 
 
The Weizmann Institute of Science in Rehovot, Israel, is one of the world's top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, the Institute is home to 2,700 scientists, students, technicians and supporting staff. Institute research efforts include the search for new ways of fighting disease and hunger, examining leading questions in mathematics and computer science, probing the physics of matter and the universe, creating novel materials and developing new strategies for protecting the environment.
 
Weizmann Institute news releases are posted on  http://www.eurekalert.org
 


 
Life Sciences
English

Weizmann Institute Scientists Discover: Antioxidants Cause Fertility Problems in Females

English
Antioxidants are sold over the counter everywhere. They’re added to food, drink and face cream. But according to Prof. Nava Dekel of the Biological Regulation Department, we still don’t have a complete understanding of how they act in our bodies. New research by Dekel and her team, recently published in the Proceedings of the National Academy of Sciences USA (PNAS), has revealed a possible unexpected side effect of antioxidants: They might cause fertility problems in females.
 
Common antioxidants include vitamins C and E. These work by eliminating molecules called reactive oxygen species that are produced naturally in the body. Stress can cause these chemically active molecules to be overproduced; in large amounts they damage cells indiscriminately. By neutralizing these potentially harmful substances, antioxidants may, theoretically, improve health and slow down the aging process.
 
But when Dekel and her research team including her former and present Ph.D. students Dr. Ketty Shkolnik and Ari Tadmor applied antioxidants to the ovaries of female mice, the results were surprising: ovulation levels dropped precipitously. That is, very few eggs were released from the ovarian follicles to reach the site of fertilization, compared to those in untreated ovaries.
 
To understand what lies behind these initial findings, the team asked whether it is possible that the process of ovulation might rely on the very ‘harmful’ substances destroyed by antioxidants – reactive oxygen species.
 
Further testing in mice showed that this is, indeed, the case. In one experiment, for instance, Dekel and her team treated some ovarian follicles with luteinizing hormone, the physiological trigger for ovulation, and others with hydrogen peroxide, a reactive oxygen species. The results showed hydrogen peroxide fully mimicked the effect of the ovulation-inducing hormone. This implies that reactive oxygen species that are produced in response to luteinizing hormone serve, in turn, as mediators for this physiological stimulus leading to ovulation.
 
Among other things, these results help fill in a picture that has begun to emerge in recent years of fertility and conception, in which it appears that these processes share a number of common mechanisms with inflammation. It makes sense, says Dekel, that substances which prevent inflammation in other parts of the body might also get in the way of normal ovulation, and so more caution should be taken when administering such substances.
 
Much of Dekel’s research has focused on fertility -- her previous results are already helping some women become pregnant. Ironically, the new study has implications for those seeking the opposite effect. Dekel: ‘On the one hand, these findings could prove useful to women who are having trouble getting pregnant. On the other, further studies might show that certain antioxidants might be effective means of birth control that could be safer than today’s hormone-based prevention.’
 
Dekel and her team are now planning further studies to investigate the exact mechanics of this step in ovulation and to examine its effect on mice when administered in either food or drink. In addition, they plan to collect data on the possible link between females being administered antioxidant supplements and the difficulty to conceive.
 

Prof. Nava Dekel’s research is supported by the M.D. Moross Institute for Cancer Research; the Jeanne and Joseph Nissim Foundation for Life Sciences Research; the Yeda-Sela Center for Basic Research; the Willner Family Center for Vascular Biology – Head; the Dwek Family Biomedical Research Fund; the Phyllis and Joseph Gurwin Fund for Scientific Advancement; and the J & R Foundation. Prof. Dekel is the incumbent of the Philip M. Klutznick Professorial Chair of Developmental Biology.
 

The Weizmann Institute of Science in Rehovot, Israel, is one of the world's top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, the Institute is home to 2,700 scientists, students, technicians and supporting staff. Institute research efforts include the search for new ways of fighting disease and hunger, examining leading questions in mathematics and computer science, probing the physics of matter and the universe, creating novel materials and developing new strategies for protecting the environment.
 
Weizmann Institute news releases are posted on the World Wide Web at http://wis-wander.weizmann.ac.il/, and are also available at http://www.eurekalert.org/
 
Life Sciences
English

A New Way to Reprogram Cells

English

 

RiPS (RNA-induced pluripotent stem) cells grow long, nerve-cell-like extensions when moved to a new substrate
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stem cells are like the proverbial fountain of youth – an elixir that might one day repair hard-used, damaged heart muscle or stop degenerative diseases. But reality still falls far short of the promise. Recent research by Prof. David Givol of the Institute’s Molecular Cell Biology Department and his colleagues may help sidestep some of the major problems involved in the medical use of stem cells.
 
Much stem cell research involves embryonic stem cells – the earliest cells in the developing embryo. Embryonic stem cells are pluripotent, that is, they retain the potential to differentiate ­­– turn into any cell type – when given the right cues. Not only does this make them invaluable for research but, theoretically, such cells could treat many problems in the body, especially diseases connected with aging as well as degenerative diseases. But because such cells are obtained solely from human embryos, their use has been extremely limited, in part due to moral issues.
 
 
(l-r) Profs. Shmuel Rozenblatt and David Givol
 

 

That’s why the discovery in 2006 by the Japanese scientist Shinya Yamanaka that ordinary adult skin cells could be reprogrammed to become embryonic stem cells rocked the world of biological research. Though such cells are not quite identical to embryonic stem cells, they appear to share their ability to differentiate into any other type of cell. Only four genes, inserted in the cells’ DNA, were sufficient to turn back the clock, changing cells whose fate had long been “fixed” into so-called iPS (induced pluripotent stem) cells.


This finding was important, says Givol, not only because of the biomedical implications, but because it overturned the long-held assumption that cell differentiation is a one-way process that can never be reversed. Though, in practice, cells get “locked” into a specialized form, in fact, all of our tissues’ cells, from stem to skin, contain the genetic tools for creating every cell type. Reprogramming them involves, in a sense, finding out how to switch certain genes on and others off in such a way that the embryonic stem cell state is reinstated. It turns out that all four reprogramming genes belong to a small group that activate other genes in the embryonic stem cells and are afterward silenced in the differentiated cells.

But these new kinds of stem cells (iPS cells) are not ready for medical applications: The problem is the very DNA used in their reprogramming. Once inserted into the genome, the DNA remains in place and continue to function. Among other things, such cells can become cancerous if the inserted bits turn on the “wrong” genes or mutate others. In principle, any integration of DNA into the genome is dangerous and unpredictable.

Since the first iPS cells were created, scientists have been searching for ways to avoid that possibility. These have included designing intricate methods for removing the inserted DNA after it has finished the job, or else attempting to introduce the products of these genes – proteins – into cells. So far, both approaches have proved problematic.

Givol, together with his colleagues Dr. Eduard Yakubov, Prof. Shmuel Rozenblatt of Tel Aviv University and Prof. Gidi Rechavi of the Sheba Medical Center and Tel Aviv University, sought a middle way. The solution they came up with is literally a “middle man” in the cell: messenger RNA (mRNA) – the strands of genetic material copied from the DNA that carry the protein-making plans from the cell’s nucleus to its protein factories, the ribosomes. RNA, they reasoned, gets degraded after a short time, so there are no issues of foreign genetic material remaining in the cell’s DNA. More importantly, RNA does not integrate into the genome and mutations are thus avoided. On the other hand, because the proteins it encodes are produced, folded and packaged in the cells’ own machinery, they should be able to function properly in the cell.
 
 
Prof. Gidi Rechavi           Dr. Eduard Yakubov
                                              

Using the four reprogramming genes, the researchers synthesized mRNA in a test tube and then inserted it into adult cells grown in culture. They repeated the procedure several times, and by the end of a week their cells were showing the expression of embryonic stem cell markers. The team observed, for instance, the activation of signature genes that are turned on only in pluripotent stem cells. And when placed on a different growth medium, the cells, which had started out as connective tissue and now were reprogrammed to be iPS cells, began to differentiate into cells with long extensions that appeared to be nerve cells.


Further experiments are needed to determine whether the new cells fulfill all of the requirements to qualify as iPS cells. But, says Givol: “We’ve proved that reprogramming with mRNA is completely possible and can be used to replace DNA for this purpose.” After publication of these results, a number of other research groups, including some that intend to develop biomedical applications, have expressed interest in the method. Givol: “RNA-induced stem (or RiPS) cells might be a way forward in the effort to develop personalized medicine. A person’s own cells could be reprogrammed, and the iPS cells could then be induced to differentiate into a specific cell type (again using mRNA). Such techniques could potentially treat a wide variety of problems, including many for which there is presently no cure.”

 

 
RiPS (RNA-induced pluripotent stem) cells grow long, nerve-cell-like extensions when moved to a new substrate
Life Sciences
English

Copaxone® - MS medication

English
Prof. Michael Sela
 
In the late 1960s, Institute scientists Profs. Ruth Arnon and Michael Sela and Dr. Dvora Teitelbaum synthesized several molecules known as copolymers. They were hoping to create an animal model for studying multiple sclerosis. Surprisingly, rather than causing symptoms of MS, the copolymers were found to block an MS-like disease in mice.
 


Application


One of the copolymers eventually became a major MS medication for humans. Produced by Teva Pharmaceuticals Ltd. under the name Copaxone®, it has been approved for marketing in Israel, the United States and Europe.
 

Prof. Michael Sela
Life Sciences
English

Antibody Fragment Used in Genetic Engineering Techniques

English
Prof. David Givol
 
Prof. David Givol spent a significant part of his career investigating the structure-function relationship of antibodies. He identified the smallest fragment of antibody containing all its binding properties, i.e. the part of the molecule responsible for recognizing the foreign substance attacking the organism.
 

Application

 
Today, this fragment – called Fv – is used in genetic engineering techniques for producing synthetic antibodies for treating various diseases.
 
Prof. David Givol
Life Sciences
English

Pages